Literature DB >> 11433531

CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.

F Petronzelli1, D Sollima, G Coppola, M E Martini-Neri, G Neri, M Genuardi.   

Abstract

The CDKN2A locus encodes two tumor suppressor proteins, p16(ink4) and p14(arf), through use of alternative first exons. CDKN2A mutations detected in melanoma families are usually missense or nonsense changes which mainly impair p16(ink4) function. Large genomic deletions spanning the entire locus have been observed in two pedigrees with melanomas and nervous tumors. We have detected a novel splice site mutation in a family with melanomas, neurofibromas, and multiple dysplastic nevi. Both alternative mRNAs produced by the mutant allele lacked shared sequences from exon 2, which encodes a substantial portion (>50%) of both p16(ink4) and p14(arf) proteins. The development of neurofibromas can be explained by cooperative effects of combined inactivation of p16(ink4) and p14(arf) or, alternatively, of p14(arf) alone. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11433531     DOI: 10.1002/gcc.1159

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

1.  High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.

Authors:  Marko Hocevar; Magdalena Avbelj; Barbara Perić; Janez Zgajnar; Nikola Besić; Tadej Battelino
Journal:  Croat Med J       Date:  2006-12       Impact factor: 1.351

Review 2.  Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis.

Authors:  Meg R Gerstenblith; Jianxin Shi; Maria Teresa Landi
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-16       Impact factor: 4.693

Review 3.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

4.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

Review 5.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 6.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

7.  Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

Authors:  Juliette Delaunay; Ludovic Martin; Brigitte Bressac-de Paillerets; Gerard Duru; Olivier Ingster; Luc Thomas
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

Review 8.  An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies.

Authors:  Maria J Baker; Alisa M Goldstein; Patricia L Gordon; Kimberly S Harbaugh; Heath B Mackley; Michael J Glantz; Joseph J Drabick
Journal:  J Med Genet       Date:  2016-01-21       Impact factor: 6.318

Review 9.  The pathobiology of splicing.

Authors:  Amanda J Ward; Thomas A Cooper
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

10.  Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

Authors:  Nicholas J Taylor; Elizabeth A Handorf; Nandita Mitra; Marie-Françoise Avril; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarrà; D Timothy Bishop; Brigitte Bressac-de Paillerets; Donato Calista; Lisa A Cannon-Albright; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Eitan Friedman; Anne-Marie Gerdes; Paola Ghiorzo; Alisa M Goldstein; Thais C Grazziotin; Johan Hansson; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Elizabeth A Holland; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Sancy A Leachman; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane Palmer; Barbara Perić; Dace Pjanova; Susana Puig; Helen Schmid; Nienke van der Stoep; Margaret A Tucker; Karin A W Wadt; Linda Whitaker; Xiaohong R Yang; Julia A Newton Bishop; Nelleke A Gruis; Peter A Kanetsky
Journal:  J Invest Dermatol       Date:  2016-01-28       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.